Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016" report to their offering.

'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016'; Metastatic Adenocarcinoma of The Pancreas pipeline therapeutics constitutes close to 34 molecules. Out of which approximately 30 molecules are developed by Companies and remaining by the Universities/Institutes.

Metastatic Adenocarcinoma of The Pancreas Metastatic pancreatic adenocarcinoma is a type of cancer that originates in the pancreas, but then spreads to other areas of the body, such as liver, lungs and bones. Symptoms include weight loss, decreased appetite, jaundice (a yellow tinge to the skin and the whites of the eyes), dark urine and pale clay-colored stools. Individuals may also experience nausea, vomiting and general malaise. The predisposing factors include family history, smoking, chronic pancreatitis and diabetes. Treatment includes surgery, chemotherapy and radiation therapy.

The report 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 3, 15, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 4 molecules, respectively.

Key Topics Covered:

1. Introduction
2. Metastatic Adenocarcinoma of The Pancreas Overview
3. Therapeutics Development
4. Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
5. Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
6. Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
7. Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
8. Metastatic Adenocarcinoma of The Pancreas Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
13. Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
14. Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development

• AbbVie Inc
• Aduro BioTech, Inc.
• Array BioPharma Inc.
• Axcentua Pharmaceuticals AB
• Berg LLC
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• CTI BioPharma Corp.
• CytRx Corporation
• Daiichi Sankyo Company, Limited
• Eleison Pharmaceuticals LLC
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Incyte Corporation
• MabVax Therapeutics Holdings, Inc.
• Merrimack Pharmaceuticals, Inc.
• NewLink Genetics Corporation
• Novartis AG
• Oncolytics Biotech Inc.
• Pfizer Inc.
• Phoenix Biotechnology, Inc.
• Targovax ASA

For more information about this report visit http://www.researchandmarkets.com/research/kcwjr5/metastatic